Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business



Aastrom Biosciences, a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks.

Through this acquisition, Aastrom is acquiring commercial rights to three marketed cell therapy products. These products include Carticel, an autologous chondrocyte implant currently marketed in the US for the treatment of articular cartilage defects, Epicel, a permanent skin replacement for burns greater than or equal to 30% of total body surface area, and MACI, a third-generation ACI product currently marketed in the EU. Aastrom will also acquire manufacturing and production centers located in the US and Denmark.

Sanofi acquired the CTRM business in 2011 through the acquisition of Genzyme Corporation.

Source: Aastrom Biosciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here